<GlossaryTerm id="CDR0000801600"><TermName>Tabrecta</TermName><TermPronunciation>(ta-BREK-tah)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat adults with non-small cell lung cancer that has spread and has a certain mutation (change) in the <GeneName>MET</GeneName> gene. It is also being studied in the treatment of other types of cancer. Tabrecta blocks a protein made by the <GeneName>MET</GeneName> gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called capmatinib hydrochloride.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000802727" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Tabrecta&quot;" language="en" id="_3"/><MediaLink ref="CDR0000802728" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Tabrecta&quot;" language="es" id="_4"/><SpanishTermName>Tabrecta</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento de adultos con cáncer de pulmón de células no pequeñas que se diseminó y tiene cierta mutación (cambio) en el gen <GeneName>MET</GeneName>. También está en estudio para el tratamiento de otros tipos de cáncer. Tabrecta bloquea una proteína que se origina del gen <GeneName>MET</GeneName>, lo que quizás ayude a impedir la multiplicación de células cancerosas y las destruya. Es un tipo de inhibidor de tirosina–cinasas. También se llama clorhidrato de capmatinib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2020-05-12</DateFirstPublished><DateLastModified>2021-09-29</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000801622" url="/about-cancer/treatment/drugs/capmatinibhydrochloride">Capmatinib Hydrochloride</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
